Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Celiac Disease Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

PIPELINE HIGHLIGHTS

Celiac Disease is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline's potential. Development of Celiac Disease medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Celiac Disease market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Celiac Disease.

Good progress is anticipated during 2020 and 2021 with Celiac Disease pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Celiac Disease pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

DRUG DEVELOPMENT PIPELINE OVERVIEW

The Celiac Disease pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Celiac Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Celiac Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Celiac Disease pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

DRUG PROFILES

Celiac Disease development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

Celiac Disease COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Celiac Disease drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Celiac Disease. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 19 Celiac Disease companies including company overview, key snapshot, contact information, and their strategies on accelerating Celiac Disease pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies Analyzed

Reasons to Buy

For more information about this report visit https://www.researchandmarkets.com/r/oz1yyq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900